Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (opens new window)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Źródło‎: Cancer 2013;119(21):3784-7.

Indeks‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (opens new window)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (opens new window)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Źródło‎: Lancet 1989;334(8655):122-4.

Indeks‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (opens new window)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (opens new window)

Ben-Bassat I, Douer D, Ramot B.

Źródło‎: Eur J Haematol 1990;45(2):86-9.

Indeks‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (opens new window)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (opens new window)

Dean A, Tuffin P.

Źródło‎: J Pain Symptom Manage 1997;13(1):20-4.

Indeks‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (opens new window)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (opens new window)

Ford PA, Grant SJ, Mick R, Keck G.

Źródło‎: J Clin Oncol 2015;33(15):1674-9.

Indeks‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (opens new window)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (opens new window)

Garewal HS, Durie BG.

Źródło‎: Scand J Haematol 1985;35(5):497-500.

Indeks‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (opens new window)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (opens new window)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Źródło‎: Cancer 2006;107(1):136-40.

Indeks‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (opens new window)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (opens new window)

Marshall A, Li A, Drucker A, Dzik W.

Źródło‎: Hematol Oncol 2016;34(3):147-53.

Indeks‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (opens new window)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (opens new window)

Prokopchuk-Gauk O, Brose K.

Źródło‎: Cureus 2015;7(12):e428.

Indeks‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (opens new window)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (opens new window)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Źródło‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indeks‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (opens new window)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (opens new window)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Źródło‎: Hematol Oncol 2008;26(4):241-6.

Indeks‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (opens new window)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (opens new window)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Źródło‎: Am J Hematol 2006;81(9):720.

Indeks‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (opens new window)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (opens new window)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Źródło‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indeks‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (opens new window)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (opens new window)

Erduran E, Bahadir A, Mutlu M.

Źródło‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Indeks‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (opens new window)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (opens new window)

Franchini M, Veneri D, Lippi G.

Źródło‎: Bone Marrow Transplant 2007;39(12):729-35.

Indeks‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (opens new window)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (opens new window)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Źródło‎: Am J Hematol 2002;69(3):219-22.

Indeks‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (opens new window)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (opens new window)

Hsieh A, Cheong I.

Źródło‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indeks‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (opens new window)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (opens new window)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Źródło‎: Haemostasis 1996;26 Suppl 1:159-64.

Indeks‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (opens new window)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (opens new window)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Źródło‎: Med Oncol 2010;27(1):16-9.

Indeks‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (opens new window)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (opens new window)

Vidarsson B, Önundarson PT.

Źródło‎: Thromb Haemost 2000;83(4):634-5.

Indeks‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (opens new window)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (opens new window)

Zver S, Andoljšek D, Černelč P.

Źródło‎: Eur J Haematol 2004;72(6):455-6.

Indeks‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (opens new window)

Management of bleeding complications of hematologic malignancies. (opens new window)

Green D.

Źródło‎: Semin Thromb Hemost 2007;33(4):427-34.

Indeks‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (opens new window)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (opens new window)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Źródło‎: Int J Lab Hematol 2013;35(4):457-9.

Indeks‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (opens new window)

Management of bleeding in patients with advanced cancer. (opens new window)

Pereira J, Phan T.

Źródło‎: Oncologist 2004;9(5):561-70.

Indeks‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (opens new window)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (opens new window)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Źródło‎: Haematologica 1997;82(5):584-7.

Indeks‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (opens new window)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (opens new window)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Źródło‎: Bull Cancer 2006;93(2):E7-12.

Indeks‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (opens new window)